**Supplementary File**

**Outcomes among HIV-positive patients hospitalized with COVID-19**

Savannah Karmen-Tuohy1&, Philip M. Carlucci1&, Fainareti N. Zervou1, Ioannis M. Zacharioudakis1, Gabriel Rebick1, Elizabeth Klein1, Jenna Reich1, Simon Jones2,3, Joseph Rahimian1

1New York University Grossman School of Medicine, Department of Medicine, New York, NY

2Division of Healthcare Delivery Science, Department of Population Health, NYU Grossman School of Medicine, New York, NY

3Center for Healthcare Innovation and Delivery Science, NYU Langone Health, New York, NY

**Supplementary Table 1**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HIV+**N = 21 | **Non-HIV**N = 42 | **P-value** |
| **Demographics** |  |  |  |
| Age, years  | 60.04 + 11.77 | 61.48 + 20.13 | 0.383 |
| Male Sex | 19 (90.5%) | 38 (90.5%) | 1.000 |
| Race |  |  | 0.065 |
|  African American | 5 (23.8%) | 4 (9.5%) | 0.127 |
|  White | 8 (38.1%) | 23 (54.8%) | 0.212 |
|  Asian  | 0 (0%) | 6 (14.3%) | 0.069 |
|  Other/Unknown | 8 (38.1%) | 9 (21.4%) | 0.160 |
| **History** |  |  |  |
| Tobacco use |  |  | 0.851 |
|  Never or Unknown | 16 (76.2%) | 31 (73.8%) |  |
|  Former | 3 (14.3%) | 5 (11.9%) |  |
|  Current | 2 (9.5%) | 6 (14.3%) |  |
| Hypertension | 7 (33.3%) | 16 (38.1%) | 0.711 |
| Hyperlipidemia | 4 (19.0%) | 9 (21.4%) | 0.826 |
| Coronary Artery Disease | 1 (4.8%) | 3 (7.1%) | 0.715 |
| Heart Failure | 0 (0%) | 0 (0%) | - |
| Peripheral Vascular Disease | 1 (4.8%) | 1 (2.4%) | 0.611 |
| Asthma or COPD | 4 (19.0%) | 6 (14.3%) | 0.361 |
| Diabetes | 4 (19.0%) | 8 (19.0%) | 1.000 |
| Malignancy | 3 (14.3%) | 3 (7.1%) | 0.363 |
| Transplant (completed) | 0 (0%) | 0 (0%) | - |
| Chronic Kidney Disease | 4 (19.0%) | 7 (16.7%) | 0.814 |
| BMI kg/m2 | 28.21 + 5.37 | 28.24 + 5.18 | 0.493 |

Data are represented as median (IQR), mean + SD, or N (%). Sample size is reported where it differed due to lab tests not performed. P-values were calculated using 2-sided t-test for parametric variables and Mann Whitney U test for nonparametric continuous variables. Pearson χ2 test was used for categorical comparisons. *P* < .05 was deemed significant.

**Supplementary Table 2**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HIV+**N = 21 | **Non-HIV**N = 42 | **P-value** |
| **COVID Treatments During Hospitalization** |  |  |  |
| Lopinavir-Ritonavir | 2 (9.5%) | 2 (4.8%) | 0.465 |
| Plaquenil | 12 (57.1%) | 27 (64.3%) | 0.582 |
| Tocilizumab | 1 (4.8%) | 0 (0%) | 0.154 |
| Azithromycin | 14 (66.7%) | 23 (54.8%) | 0.366 |
| Zinc | 5 (23.8%) | 8 (19.0%) | 0.660 |
| Intravenous immunoglobulin (IVIG) | 1 (4.8%) | 0 (0%) | 0.154 |
| Nitazoxanide  | 2 (9.5%) | 3 (7.1%) | 0.742 |
| Remdesivir | 0 (0%) | 0 (0%) | - |
| Corticosteroids | 4 (19.0%) | 0 (0%) | **0.003** |

Data are represented as N (%).P-values were calculated using. Pearson χ2 test was used for categorical comparisons. *P* < .05 was deemed significant.